C
Charles G. Caldwell
Researcher at Merck & Co.
Publications - 55
Citations - 2047
Charles G. Caldwell is an academic researcher from Merck & Co.. The author has contributed to research in topics: Septic arthritis & Dipeptidyl peptidase. The author has an hindex of 29, co-authored 55 publications receiving 2019 citations.
Papers
More filters
Patent
Pyrrolidine modulators of chemokine receptor activity
Charles G. Caldwell,Kevin T. Chapman,Jeffrey J. Hale,Dooseop Kim,Christopher L. Lynch,Malcolm MacCoss,Sander G. Mills,Keith G. Rosauer,Christopher A. Willoughby,Scott C. Berk +9 more
TL;DR: In this article, pyrrolidine compounds of formula (I) wherein R?1, R2, R3, R4, R5, R6? and n are defined herein) which are useful as modulators of chemokine receptor activity are presented.
Patent
Cyclic amine modulators of chemokine receptor activity
Charles G. Caldwell,Paul E. Finke,Malcolm MacCoss,Laura C. Meurer,Sander G. Mills,Bryan Oates +5 more
TL;DR: In this paper, the present invention is directed to cyclic amines of formula (I), (wherein R?1, R2, R3?, m and n are defined herein) which are useful as modulators of chemokine receptor activity.
PatentDOI
Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
Craig K. Esser,William K. Hagmann,William F. Hoffman,Shrenik K. Shah,Kenny K. Wong,Renee M. Chabin,Ravindra K. Guthikonda,Malcolm MacCoss,Charles G. Caldwell,Philippe L. Durette +9 more
TL;DR: 4,6-Disubstitution enhanced both potency and specificity for the inducible NOS with the most potent compound having an IC50 of 28 nM.
Patent
3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Wallace T. Ashton,Charles G. Caldwell,Robert J. Mathvink,Hyun O. Ok,Leah Bitalac Reigle,Ann E. Weber +5 more
TL;DR: In this paper, a 3-amino-4-phenylbutanoic acid derivatives which are inhibitors of the dipeptidyl peptidyl enzyme-IV enzyme ('DP-IV inhibitors') and which are useful in the treatment or prevention of diseases in which the PD enzyme is involved, such as diabetes and particularly type 2 diabetes.
Journal ArticleDOI
Substituted 4,6-diaminoquinolines as inhibitors of C5a receptor binding
Thomas J. Lanza,Philippe L. Durette,Thomas E. Rollins,Salvatore J. Siciliano,Dana N. Cianciarulo,Sumire V. Kobayashi,Charles G. Caldwell,Martin Springer,William K. Hagmann +8 more
TL;DR: Tests revealed a narrow profile of potency for effective C5a receptor binding inhibition using substituted 4,6-diaminoquinolines and 6-N-(2-chlorocinnamoyl)-4-amino-2-methyl-6-quinolyl)urea and 7-N-[6-N]-2- chlorocinn amoyl-4-Diamino- 2-methylquinoline.